The effect of a statin treatment conducted for a longer period of time or in a larger population of patients should be evaluated to confirm the findings of our study. The reported results do not challenge the use of statins in all the cardiovascular disorders for which they are strongly recommended. The study was planned, conducted, and analysed by the GISSI group which has full ownership of the data, in complete independence from AstraZeneca that concurred to fund the study. AstraZeneca also provided the experimental treatment.
Conflict of interest: L. The most important acknowledgement is to the participants in the study and to the cardiologists, nurses, ethical committees, and administrative staff in hospitals who assisted with its conduct.
All members of the Steering and Writing Committees had full access to the database. All members reviewed the paper and unanimously agreed to submit it to the European Heart Journal. Google Scholar. To our knowledge, permanent AF was associated with poor outcomes in heart failure.
After subtracting the events rate of patients for worsening heart failure from those for cardiovascular hospitalization, the difference was obviously privileged on the side of rosuvastatin as compared to the placebo HR: 0.
On the contrary, the benefits of rosuvastatin to reduce events rate of patients for worsening heart failure were mainly obtained from the prevention of coronary events in the high hs-CRP subgroup AF vs.
Further, rosuvastatin demonstrated no advantage with regard to patients for cardiovascular hospitalization discounting those for worsening heart failure HR: 0. We presumed that the calculation of difference would eliminate the effect of permanent AF at baseline on higher rates of worsening heart failure, stroke and sudden death, and the left value possibly reflected more accurate results. In addition, the treatment of rosuvastatin in the prevention of AF was reported to be effective for those with heart failure except those with advanced stage and diabetes in analysis of the GISSI-HF trial.
From the view of the point, the treatment of rosuvastatin seemed to improve the primary end points regardless of the high or the low hs-CRP subgroups. In summary, rosuvastatin reduced the cardiovascular events rate and the need for hospitalization by reduction of either coronary events in the high hs-CRP subgroup or cerebrovascular accidents in the low hs-CRP subgroup which overwhelmed its adverse effects on patients with ischemic heart failure.
Circulation ; Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol. Effect of rosuvastatin in patients with chronic heart failure the GISSI-HF trial : a randomized double-blind, placebo-controlled trial.
Lancet ; Eur Heart J ; Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Sign In. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation.
Volume Article Contents Abstract. Fast Track. Maggioni , Aldo P. Oxford Academic. Gianna Fabbri. Donata Lucci. Roberto Marchioli. Maria Grazia Franzosi. Roberto Latini.
Gian Luigi Nicolosi. Maurizio Porcu. Franco Cosmi. Severo Stefanelli. Gianni Tognoni , Gianni Tognoni. Luigi Tavazzi. Revision received:. Cite Cite Aldo P. Select Format Select format. Permissions Icon Permissions. Abstract Aims. Atrial fibrillation , Heart failure , Rosuvastatin. Figure 1. Open in new tab Download slide. Table 1 Baseline characteristics of patients. P -value. Open in new tab. Figure 2. Kaplan—Meier curves for time to new onset of atrial fibrillation.
Table 3 Effects of rosuvastatin on the occurrence of atrial fibrillation: unadjusted and multivariable analyses. Unadjusted analysis 0. Table 4 Pre-defined subgroup analysis: time to new onset of atrial fibrillation. Google Scholar Crossref. Search ADS. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe.
Part 1: patient characteristics and diagnosis. Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. A randomized, double-blind, placebo-controlled study. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Amiodarone to prevent recurrence of atrial fibrillation.
Canadian Trial of Atrial Fibrillation Investigators. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. Improving survival for patients with advanced heart failure: a study of consecutive patients.
Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Improving survival for patients with atrial fibrillation and advanced heart failure. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials.
Effect of rosuvastatin in patients with chronic heart failure the GISSI-HF trial : a randomised, double-blind, placebo-controlled trial. Rationale and design of the GISSI Heart Failure Trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure the GISSI-HF trial : a randomised, double-blind, placebo-controlled trial.
Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity CHARM program. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.
Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery study. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Statin use and development of atrial fibrillation: a systematic review and metanalysis of randomized clinical trials and observational studies.
Prevention of atrial fibrillation with 3-hydroxymethylglutaryl coenzyme A reductase inhibitors. Published on behalf of the European Society of Cardiology. All rights reserved. For permissions please email: journals. Issue Section:. Download all slides.
Supplementary data. AddSuppFiles-4 - ppt file. AddSuppFiles-3 - jpg file. AddSuppFiles-2 - ppt file. Randomization 1 R1 : n-3 PUFA 1 g daily vs corresponding placebo; Randomization 2 R2 : rosuvastatin 10 mg daily vs corresponding placebo. To demonstrate that, in patients with heart failure treated at the best of recommended therapies, long term administration of a n-3 PUFA, b rosuvastatin is more effective than the corresponding placebo in the reduction of:.
To assess that long term administration of a n-3 PUFA, b rosuvastatin is more effective than corresponding placebo in the reduction of:. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. Try the modernized ClinicalTrials. Learn more about the modernization effort. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms.
Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : August 14, Study Description. Detailed Description:. FDA Resources. Arms and Interventions. Outcome Measures. Primary Outcome Measures : All-cause mortality [ Time Frame: from enrollment to deaths in R2 arm ] All cause mortality or hospitalizations for any reason [ Time Frame: from enrollment to deaths ].
Secondary Outcome Measures : Cardiovascular mortality [ Time Frame: from enrollment to deaths in R2 arm ] Cardiovascular mortality or hospitalization for heart failure or for any reasons [ Time Frame: from enrollment to deaths in R2 arm ] Sudden cardiac death [ Time Frame: from enrollment to deaths in R2 arm ] Hospitalizations for any reasons [ Time Frame: from enrollment to deaths in R2 arm ] Hospitalization for Cardiovascular reasons [ Time Frame: from enrollment to deaths in R2 arm ] Hospitalization for congestive heart failure [ Time Frame: from enrollment to deaths in R2 arm ] Miocardial infarction [ Time Frame: from enrollment to deaths in R2 arm ] Stroke [ Time Frame: from enrollment to deaths in R2 arm ].
Eligibility Criteria. Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials. Valdarno "S. Michele S. Brotzu - S. Ospedaliera S. Anna e S. Ospedaliero S. More Information. Additional Information: Related Info. Related Info. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure the GISSI-HF trial : a randomised, double-blind, placebo-controlled trial.
Epub Aug Effect of rosuvastatin in patients with chronic heart failure the GISSI-HF trial : a randomised, double-blind, placebo-controlled trial. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure.
Eur J Heart Fail.
0コメント